歡迎您，來(lái)到青旗（上海）生物技術(shù)發(fā)展有限公司！
歡迎您，來(lái)到青旗（上海）生物技術(shù)發(fā)展有限公司！
您的位置：網(wǎng)站首頁(yè) > 產(chǎn)品展示 > 細胞庫 > 細胞系 > 人胰腺癌細胞Capan-2
Related articles
簡(jiǎn)要描述：青旗（上海）生物技術(shù)發(fā)展有限公司，總部位于上海浦東新區，依托本地高校資源，逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓為一體的綜合化產(chǎn)業(yè)平臺，在標準化細胞庫建立及細胞藥物前端模型方面成果顯著(zhù)。公司生產(chǎn)經(jīng)營(yíng)原代細胞、細胞系、ELISA試劑盒、感受態(tài)細胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶(hù)負責的態(tài)度，以對科研的高度嚴謹，以嚴格的質(zhì)量控制，為廣大生物醫學(xué)科研用戶(hù)提供更優(yōu)質(zhì)的服務(wù)！
更新時(shí)間：2021-05-27
廠(chǎng)商性質(zhì)：生產(chǎn)廠(chǎng)家
瀏覽次數：401
| 品牌 | 其他品牌 | 貨號 | BFN60807521 |
|---|---|---|---|
| 規格 | T25培養瓶x1 1.5ml凍存管x2 | 供貨周期 | 現貨 |
| 主要用途 | 僅供科研 | 應用領(lǐng)域 | 醫療衛生,生物產(chǎn)業(yè) |
細胞名稱(chēng) | 人胰腺癌細胞Capan-2 |
| |
貨物編碼 | BFN60807521 | ||
產(chǎn)品規格 | T25培養瓶x1 | 1.5ml凍存管x2 | |
細胞數量 | 1x10^6 | 1x10^6 | |
保存溫度 | 37℃ | -198℃ | |
運輸方式 | 常溫保溫運輸 | 干冰運輸 | |
安全等級 | 1 | ||
用途限制 | 僅供科研 2類(lèi) | ||
培養體系 | 90%DMEM+10%FBS+1%雙抗 | ||
培養溫度 | 37℃ | 二氧化碳濃度 | 5% |
簡(jiǎn)介 | 人胰腺癌細胞Capan-2取自56歲男性供體。該細胞源于ATCC | ||
注釋 | Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: NCI RAS program mutant KRAS cell line panel. From: Memorial Sloan Kettering Cancer Center; New York; USA. Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2000-049. Doubling time: 96 hours (PubMed=3019537); 45-60 hours (CLS); ~50-70 hours (DSMZ). Microsatellite instability: Stable (MSS) (Sanger). Omics: Array-based CGH. Omics: Deep antibody staining analysis. Omics: Deep exome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Metabolome analysis. Omics: Proteome analysis by 2D-DE/MS. Omics: SNP array analysis. Omics: Transcriptome analysis. Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814. Misspelling: CANPAN-2; In Cosmic 2434087. | ||
基因突變 | Heterozygous for KRAS p.Gly12Val (c.35G>T) (PubMed=8026879; PubMed=8426738; PubMed=11169959; PubMed=15367885). TP53 p.Thr125Thr (c.375G>T); impairs TP53 splicing dramatically (PubMed=8026879; PubMed=24700732). | ||
HLA信息 | / | ||
STR信息 | Amelogenin X CSF1PO 11,12 D3S1358 17,18 D5S818 11,12 D7S820 9,11 D8S1179 12,13 D13S317 11,12 (ATCC; CLS; Cosmic-CLP; KCLB; PubMed=25877200) 11,12,13 (DSMZ) D16S539 9,13 D18S51 13 D21S11 31 FGA 21,24 Penta D 13,15 Penta E 11 TH01 9.3 TPOX 8 vWA 17 (ATCC; CLS; Cosmic-CLP; PubMed=25877200) 16,17 (DSMZ) 17,19 (KCLB) | ||
參考文獻 | PubMed=27259358; DOI=10.1074/mcp.M116.058313 Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J., Daly R.J. Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling. Mol. Cell. Proteomics 15:2671-2685(2016)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31037374; DOI=10.1007/s00216-019-01814-1 Lagies S., Schlimpert M., Braun L.M., Kather M., Plagge J., Erbes T., Wittel U.A., Kammerer B. Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry. Anal. Bioanal. Chem. 411:6319-6328(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) | ||
青旗（上海）生物技術(shù)發(fā)展有限公司，總部位于上海浦東新區，依托本地高校資源，逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓為一體的綜合化產(chǎn)業(yè)平臺，在標準化細胞庫建立及細胞藥物前端模型方面成果顯著(zhù)。公司生產(chǎn)經(jīng)營(yíng)原代細胞、細胞系、ELISA試劑盒、感受態(tài)細胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶(hù)負責的態(tài)度，以對科研的高度嚴謹，以嚴格的質(zhì)量控制，為廣大生物醫學(xué)科研用戶(hù)提供更優(yōu)質(zhì)的服務(wù)！
地址：上海市浦東新區宏祥北路83號
郵箱：cellsupport@bluefcell.com
傳真：
咨詢(xún)電話(huà)